Archivos de Etiqueta: Stargardt

Noticia Stargargt

Nanoscope Therapeutics has received IND clearance from the FDA to begin a Phase 2 trial of its Multi-Characteristic Opsin ambient-light activatable optogenetic monotherapy to restore vision in Stargardt patients. Nanoscope Therapeutics Inc. announced today that it has received IND clearance from the FDA to begin a Phase 2 trial of its Multi-Characteristic Opsin (MCO-010) ambient-light…
Leer más

Accesibilidad